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Abstract
Background: Chronic tendon injuries, also known as tendinopathies, are common among professional and
recreational athletes. These injuries result in a significant amount of morbidity and health care expenditure, yet
little is known about the molecular mechanisms leading to tendinopathy.
Methods: We have used histological evaluation and molecular profiling to determine gene expression changes in
23 human patients undergoing surgical procedures for the treatment of chronic tendinopathy.
Results: Diseased tendons exhibit altered extracellular matrix, fiber disorientation, increased cellular content and
vasculature, and the absence of inflammatory cells. Global gene expression profiling identified 983 transcripts with
significantly different expression patterns in the diseased tendons. Global pathway analysis further suggested
altered expression of extracellular matrix proteins and the lack of an appreciable inflammatory response.
Conclusions: Identification of the pathways and genes that are differentially regulated in tendinopathy samples
will contribute to our understanding of the disease and the development of novel therapeutics.
Background
Chronic injuries to the Achilles, patellar, extensor carpi
radialis brevis, and supraspinatus tendons remain a
common problem for both elite and recreational ath-
letes, as well as for individuals engaging in repetitive
activities. These overuse type injuries account for 30-
50% of all sports injuries and result in a significant
amount of morbidity and health care expenditure [1].
Histologic studies have shown that the primary
pathology is not inflammation as implied by the com-
monly used term “tendonitis.” Instead, samples of dis-
eased tendons show collagen degeneration, fiber
disorientation, mucoid ground substance, hypercellular-
ity, vascular ingrowth, and relative absence of inflamma-
tory cells under light microscopy [2-4]. Tendinopathy
(or tendinosis) is now the term most commonly used to
describe the clinical entity and histologic findings. Inter-
estingly, these findings are common to all tendinopa-
thies, suggesting a similar etiology and pathophysiology.
The etiology of tendinopathy remains unclear, but most
believe that a combination of extrinsic and intrinsic factors
is responsible. The extrinsic theory suggests that direct
mechanical contact leads to tendon fiber micro-damage
and subsequent injury of the tendon that eventually results
in weakness and pain. An example is impingement of the
acromion on the supraspinatus tendon, which serves as
the rationale behind acromioplasty surgery [5]. The intrin-
sic theory suggests that the tendon itself becomes inher-
ently degenerative, probably as a result of microscopic
fiber failure leading to accumulation of damage due to
inability of the tendon to self-repair. Local ischemia may
also be a contributory factor. Studies on the supraspinatus
tendon have shown that its mid-portion is relatively hypo-
vascular [6]. This lack of perfusion may result in the for-
mation of oxygen free radicals or other molecules that
initiate the pathological process.
Several observations have been made about the mole-
cular mediators of tendinopathy. Tenocyte apoptosis or
“programmed cell death” has been shown to occur at an
increased frequency in tendinopathy specimens [7]. Free
radicals as well as cyclic loading may induce the activa-
tion of molecules that lead to apoptosis [8,9]. In addi-
tion, animal studies have shown that various cytokines
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portionately expressed in tendinopathy specimens. The
application of cyclic strain has been shown to increase
the production of prostaglandin E2 (PGE2), interleukin-
6 (IL6), and IL1b [10,11]. IL1b in turn increases the pro-
duction of MMP1, MMP3, and PGE2 [12]. Alfredson et
al. studied samples from patients with Achilles tendino-
pathy and found downregulation of MMP3 mRNA and
upregulation of MMP2 and vascular endothelial growth
factor compared with control samples [13]. Riley et al.
reported decreased MMP3 and MMP2 mRNA activity,
with an increase in MMP14 [14]. These studies show
that an imbalance in cytokines and MMPs exists in dis-
eased tendons and probably contributes to the patho-
physiology; however, inconsistencies in the expression of
specific molecules in various studies indicate that more
research needs to be done.
Currently, the only non-surgical therapies available to
patients who suffer from chronic tendinopathies are
physical therapy, activity modification, non-steroidal
anti-inflammatory medications (NSAIDs), and steroid or
platelet-rich plasma injections. These therapies offer
unpredictable results, and in the case of steroids, can
lead to serious side effects and more rapid degeneration
of the tendon. By understanding the molecular media-
tors that lead to tendinopathy, novel therapeutic targets
could potentially be identified for drug development.
This will result in more effective treatments while mini-
mizing side effects.
Microarray analysis has become a powerful tool in
drug development. Microarrays allow researchers to
screen samples of tissue for the expression of thousands
of genes encoded in the human genome. This “shotgun”
approach can identify which genes are active in a given
sample by quantifying the production of specific
mRNAs. Identification of the products of these mRNAs
and their functions can serve to direct future research
and development.
The purpose of this study was to investigate whether
there is selective regulation of certain cytokines, matrix
metalloproteinases, and protein kinases in human sam-
ples of tendinopathy compared with normal tendons, as
evidenced by microarray analysis. Specifically, we were
interested in determining which specific cytokines and
degenerative enzymes are upregulated, and which are
downregulated, in diseased samples compared with nor-
mal control tendons from the same patients. This infor-
mation may contribute to the development of drugs that
can selectively modulate the disease process.
Methods
Subjects
All protocols were approved by the Institutional Review
Board at the Hospital for Special Surgery and informed
consent was obtained from each participant. A prospec-
tive study was initiated to collect tissue from patients
undergoing surgery as standard of care for tendinopathy.
Biopsies (~3 mm
3) of diseased tendons and a section of
grossly normal appearing tendon were collected from 35
patients. Written informed consent was obtained from
all patients prior to any study-related procedure. Infor-
mation on patient demographics, diagnosis, prior treat-
ments, current procedures, and operative findings was
collected and is presented in Table 1. Patients with a
diagnosis of inflammatory arthritis (such as rheumatoid
arthritis or lupus) or those who had prior surgery on
the involved tendon were excluded. Patients who
received prior corticosteroid injection were included and
this information was recorded.
RNA Preparation and Hybridization
RNA extraction and isolation were performed as pre-
viously described [15]. Fifty nanograms of RNA was
labeled using the WT-Ovation FFPE System (Nugen, San
Carlos, CA). Labeled cDNA was hybridized to GeneChip
®
Human Genome U133 2.0 arrays according to the manu-
facturer’s protocol (Affymetrix, Santa Clara, CA). For each
array, all probe sets were normalized to a mean signal
intensity value of 100. The default GeneChip Operating
Software statistical values were used for all analyses. The
raw microarray data has been deposited in the Gene
Expression Omnibus (GEO) database http://www.ncbi.
nlm.nih.gov/projects/geo/ as accession number GSE26051.
Identification of Differentially Expressed Genes
Expression values for all probe sets were subjected to
locally weighted scatterplot smoothing (LOWESS) trans-
formation. Correlation analysis and hierarchical cluster-
ing verified that all samplesh a ds i m i l a rp a t t e r n so f
expression. Only transcripts that were called as present
in 65% of the samples and expressed greater than 35
signal units in either the normal or diseased samples
were used for further analysis. Expression values were
log2 transformed and transcripts were considered differ-
entially regulated if the p-value based on a paired t-test
analysis was < 0.01 and the average fold change was
greater than 1.5. Extensive clinical information was col-
lected for each patient. Analysis of variance models were
constructed to determine whether any differences in
expression could be explained by differences in histolo-
gical disease score, disease duration, gender, steroid use,
or NSAID use. Values presented are expressed as mean
± standard error of the mean. Differences were consid-
ered statistically significant for p < 0.01.
Identification of Significantly Regulated Gene Sets
Significantly regulated biological pathways were identi-
fied using a modified version of the sigPathway
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routine and using gene sets collections C1 to C5 defined
by the Molecular Signatures Database (MSigDB) [17]. A
gene set was considered significant when q1 ≤0.05 and
q2 ≤0.05, where q1 or q2 are the permutation-based
false-discovery rates for the Q1 or Q2 hypotheses (see
[18] for an explanation of Q1 and Q2). These cut-offs
were met by1761 gene sets, which can be considered as
differentially expressed.
Histology
Tissue samples were frozen and sectioned for histologi-
cal analysis. Sections were processed using standard pro-
cedures, including Alcian blue (AB) staining. Sections
were scored on four categories: intratendinous cellular
proliferation, intratendinous vascular proliferation, intra-
tendinous glycosaminoglycan (GAG) accumulation, and
intratendinous fiber disorientation. Each category was
scored based on a 5-point scale, from 0 for normal, 3
for moderate, and 5 for severe, by two independent
histologists.
Results
Analysis of Tendinopathy Tissue Samples
Diseased and normal tendons were collected from 35
patients with rotator cuff tendinopathy, lateral epicondylitis
(tennis elbow), patellar tendinopathy, or chronic Achilles
tendinopathy who were undergoing surgery as standard of
care treatment for tendinopathy. Tendinopathy was con-
firmed both macroscopically and microscopically. The dis-
eased tendon appeared dull, yellow, and soft compared with
normal tissue, which is shiny, white, and firm. Normal ten-
don tissue had relatively few cells, contained little vascula-
ture, and had collagen fibers aligned in the direction of
force. All diseased tendons had a similar loss of normal
fibrillar structure and changes in cell orientation, which are
histological characteristics of tendinopathy [2,19,20]. All dis-
eased tissue had an increased number of fibroblasts,
increased vasculature, and increased glycosaminoglycan
staining (GAG content) although the degree of increase
in each of the parameters was variable between patients (Fig-
ure 1, Table 2). There was little evidence of any inflamma-
tory cells in either the tendon or the surrounding paratenon.
Table 1 Demographics and patient clinical diagnosis
ID Age Sex Diagnosis Duration of Sx (months) Num of Inject* Pathology Sample Control Sample
5 45 M Distal Biceps Rupture 0.3 Distal Biceps Brachialis
9 48 M ECRB tear 12 ECRB EDC
10 41 M Patella Tendon Rupture 0.1 Patella Quad tendon
12 62 M Flexor/Pronator 18 1 flexor/pronator Distal Flexor/Pronator
13 62 F RTC tear 48 2 Supraspinatus Subscap
15 32 M Patella Tendon Tear 3 Patella tendon Nl Patellar Tendon
16 61 F RTC tear 24 2 Supraspinatus Subscap
17 59 M RTC tear 6 1 Supraspinatus Subscap
19 45 M Flexor/Pronator 18 3 flexor/pronator Distal Flexor/Pronator
20 63 F RTC tear 9 1 Supraspinatus Subscap
21 65 F RTC tear 3 1 Supraspinatus Biceps
23 64 F RTC tear 8 1 Supraspinatus Subscap
24 50 M RTC tear 18 1 Supraspinatus Biceps
26 55 M ECRB tear 4 ECRB Distal ECRB
27 50 M RTC tear 4 Supraspinatus Normal RTC
28 41 M Supra tear (PT), OA, Bankart >24 Supraspinatus Biceps Tendon
29 46 M RTC tear, Adhesive Capsulitis 4 Supraspinatus Biceps Tendon
30 52 M ECRB tear 12 ECRB ECRL
31 66 M RTC tear 6 Supraspinatus Subscap
32 46 F RTC tear 2 1 Supraspinatus Teres minor
33 44 M RTC tear 6 1 Supraspinatus Subscap
34 59 F RTC tear 1 3 Supraspinatus Biceps
35 49 F RTC tear 24 Supraspinatus Subscap
*Number of corticosteroids injections.
ECRB Extensor Carpi Radialis Brevis.
RTC Rotator Cuff.
OA Osteoarthitis.
EDC extensor digitorum comunis.
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Global transcriptional analysis using Affymetrix genome-
wide U133 2.0 Plus arrays identified 20055 transcripts
expressed in 23 pairs of normal and diseased tendons
that passed quality control filters. Of these, 983 tran-
scripts were differentially regulated based on a paired t-
test (p < 0.01, fold change ≥1.5. Among the top regu-
lated genes were a disintegrin and metalloprotease 12
(ADAM12), tenascin C (TNC), periostin (POSTN), and
interleukin 13 receptor alpha 2 (IL13RA2;F i g u r e2 ,
Table 3). An analysis of covariance (ANCOVA) showed
little relationship between the age of the patient and the
level of gene expression for most transcripts. Further-
more, ANCOVA analysis suggested that < 1.2% of the
transcripts showed any relationship between gene
expression and histological disease score, disease dura-
t i o n ,s t e r o i du s e ,N S A I Du s e ,g e n d e r ,o rd u r a t i o no f
symptoms.
Global pathway analysis, based on a modified sigPath-
way algorithm [16], identified increased expression of
genes involved in the extracellular matrix, including
genes involved in focal adhesion, integrin signaling, and
collagen synthesis. In addition, expression of genes
involved in cell cycle progression, TGFb signaling, and
NFB signaling was increased (Table 4). This global
pathway analysis did not suggest that cytokines as a
whole were differentially regulated. However, of the 426
transcripts annotated by Gene Ontology as cytokines,
cytokine signaling molecules, or related to cytokines, six
were differentially regulated in diseased tendons, includ-
ing chemokine-like factor super family 4 (CMTM4),
interleukin 13 receptor alpha 2 (IL13RA2), interleukin
17D (IL17D), and interleukin 4 receptor (IL4R) (Table 5).
Consistent with a role in increased matrix turnover,
tendonopathy tissue exhibited increased expression of
genes encoding MMPs (Table 6) and genes encoding
collagens (Table 7). The majority of collagens interro-
gated showed a modest 2-fold increase in expression in
diseased tendons. Diseased tendons also showed
increased expression of several enzymes that mediate
collagen breakdown, including MMP2, MMP9, MMP14,
MMP13,a n dMMP19.W h i l em a n yM M Pg e n e sw e r e
induced in diseased tendons, not all transcripts encoding
MMPs were upregulated; in fact, MMP3 and MMP24
were significantly downregulated in diseased tissue. Of
the four known tissue inhibitors of metalloproteases
(TIMPs), only expression of TIMP1 was increased. No
ADAMTS (a disintegrin and metalloprotease with
thrombospondin motifs) family members were differen-
tially regulated based on our cut-offs.
Diseased tendons showed increased expression of a
number of relevant and important signaling pathways;
for example the fibroblast growth factors FGFR1 (1.7-
fold) and FGFR2 (2.7-fold), and genes in the Notch sig-
naling pathway, including JAG1 (3.1-fold) and Notch3
(3.6-fold). There was also evidence for increased WNT
signaling. Among the highest regulated transcripts, four
are involved in WNT signaling: WISP1 (4.2-fold), DKK3
(3.6-fold), WNT3 (3.6-fold), and LEF1 (4.1-fold). Addi-
tionally, tendinopathy tissue showed differential expres-
sion of other WNT pathway genes, including increased
expression of CTNNB (1.5-fold), WNT5a (2.7-fold), and
FZD1 (1.7-fold) and decreased expression of LRP5 (0.59-
fold) and FRZB (0.35-fold).
We found little evidence for endochondral ossification
even though this has been reported in Achilles and
patella tendinopathy [21]. Histological evaluation failed
to identify any gross areas of ossification in any of the
patients and RNA analysis did not show increased
expression of the bone markers osteocalcin or osterix.
However, expression of CBFA1, a transcription factor
associated with osteoblast differentiation, was increased
1.8-fold and that of RANKL, a key factor for osteoclast
differentiation and activation, was increased 4.0-fold in
diseased tendons.
In addition to the global pathway analysis, we specifi-
cally investigated the regulation of kinases in diseased
tendons (Table 8). The most statistically significant
regulated kinase is diseased tendons is the thousand and
Figure 1 Histological evaluation of human tendinopathy.
Representative diseased tendons were stained with Alcian blue to
visualize the proteoglycans in patient 12 (A), patient 10 (B), patient
15 (C), patient 24 (D), patient 25 (E), and patient 32 (F). Only a few
bundles from patient 12 appear normal. The remaining sections
show highly disorganized tissues with increased cell proliferation,
increased vasculature, and/or increased GAG content. Scale bar is
200 μM.
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fold increase in expression. TAOK1 activates the p38
MAP kinase pathway and tendonopathy tissue also
showed increased expression of multiple MAP kinases,
including MAP3K2 (1.8-fold), MAP4K5 (1.9-fold), and
MAPK8 (2.0-fold).
Discussion
We have evaluated gene expression and histological
changes associated with human tendinopathy. While
gene expression changes in human tendinopathy have
previously been described [13,22,23], this study repre-
sents the largest and most complete study to date. How-
ever, our study has several limitations. First, control
tendons were taken from the same joints as the diseased
tendons. These control tendons appeared normal
macroscopically but their proximity to the diseased ten-
don may have some effect on the control tendon.
Furthermore, the control tendon was an anatomically
distinct tendon exposed to different loads and strains
and it is not known how this may affect the gene
expression profile. Moreover, the tendon specimens
were collected from a heterogeneous population with
differences in age, gender, symptoms, duration of dis-
ease, and physical activity (Table 1). While changes in
Table 2 Intratendinous tendinopathy score
a
Patient
b Cellular Proliferation Vascular Proliferation GAG Accumulation Fiber Disorientation Total Score
5 3.5 1.5 1.5 5 11.5
95 2 5 5 1 7
10 4.5 5 5 5 19.5
12 4 5 1 5 15
13 5 1 3.5 5 14.5
15 5 5 5 4.5 19.5
16 3.5 2.5 2 5 13
17 5 4.5 3 5 17.5
19 4.5 5 3 5 17.5
20 5 3 3 5 16
21 5 1 2 5 13
23 4.5 3 4 5 16.5
24 5 5 3 5 18
26 5 3 5 5 18
27 4.5 3 1 5 13.5
28 5 1.5 5 5 16.5
29 5 5 5 5 20
30 4 4.5 3 4.5 16
31 4.5 1.5 4 5 15
32 4.5 1.5 5 5 16
33 5 0.5 4 5 14.5
34 5 0.5 3 5 13.5
35 5 5 3 5 18
aAverage of two independent histologist evaluation.
bNormal tendon were scored 0 in all fields.
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Figure 2 Expression levels of genes that are differentially
regulated in tendinopathy. Messenger RNA expression levels for
(A) a disintegrin and metalloproteinase domain 12 (ADAM12), (B)
tenascin C (TNC), (C) periostin (POSTN), (D) interleukin 13 receptor
alpha 2 (IL13RA2) in tendons from patients with tendinopathy.
Values represent the relative expression values as determined by
microarray analysis.
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ences, they all contribute to variations in the data.
Given the vast variation in the human population, we
reasoned that control samples from the same patients
would be a better control for interpatient variability
than tendons from control patients without any tendon
symptoms.
Progression of tendinopathy is dependent on extracel-
lular matrix integrity and remodeling of the tendon is a
common feature of tendinopathy [24]. The extracellular
matrix of normal tendons consists of many of structural
proteins (collagens) and proteoglycans. Collagen is the
main component of tendons and type I collagens
account for 65% to 80% of the total tendon mass [25].
mRNA levels for type I and type III collagens (COL1A1,
COL1A2,a n dCOL3A1) were increased in the diseased
tendons. Tendons also contain several proteoglycans,
although none of the proteoglycans analyzed (including
aggrecan, versican, decorin, biglycan, fibromodulin, and
lumican) showed increased expression in diseased
Table 3 Top regulated transcripts in human tendinopathy as determined by microarray analysis
Gene Symbol Description p-value q-value Fold Change
ADAM12 A disintegrin and metalloproteinase domain 12 1.57E-05 2.09E-04 5.6
AP3M1 Adaptor-related protein complex 3, mu 1 subunit 1.24E-03 1.91E-03 1.7
ARL7 ADP-ribosylation factor-like 7 1.43E-03 2.11E-03 4.0
ARPC5 Actin related protein 2/3 complex, subunit 5 3.63E-05 2.10E-04 1.8
ASXL1 Additional sex combs like 1 (Drosophila) 1.11E-03 1.78E-03 1.8
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa 4.18E-05 2.10E-04 2.5
BACE2 Beta-site APP-cleaving enzyme 2 3.17E-06 8.01E-05 1.9
BNC2 Basonuclin 2 1.08E-04 3.15E-04 2.9
CA12 Carbonic anhydrase XII 3.57E-05 2.10E-04 2.8
CTHRC1 Collagen triple helix repeat containing 1 5.20E-04 1.10E-03 4.4
DDEF1 Development and differentiation enhancing factor 2.83E-05 2.10E-04 2.1
DOCK10 Dedicator of cytokinesis 10 7.91E-03 8.11E-03 3.3
EDIL3 EGF-like repeats and discoidin I-like domains 3 4.80E-03 5.34E-03 2.9
FOXP1 Forkhead box P1 4.67E-05 2.10E-04 1.7
GPR161 G protein-coupled receptor 161 2.76E-04 6.89E-04 1.9
IGFBP3 Insulin-like growth factor binding protein 3 7.29E-03 7.67E-03 3.5
IL13RA2 Interleukin 13 receptor, alpha 2 2.80E-03 3.50E-03 3.5
ILK Integrin-linked kinase 1.00E-04 3.15E-04 1.6
IQGAP1 IQ motif containing GTPase activating protein 1 4.73E-05 2.10E-04 1.5
ITGB1 Integrin, beta 1 3.52E-04 8.29E-04 1.7
ITPKB Inositol 1,4,5-trisphosphate 3-kinase B 7.37E-04 1.34E-03 2.5
JAG1 Jagged 1 (Alagille syndrome) 1.90E-03 2.52E-03 3.1
KCNE4 Potassium voltage-gated channel 4 8.19E-03 8.19E-03 3.4
LAMA4 Laminin, alpha 4 6.73E-04 1.31E-03 3.4
LRRC15 Leucine rich repeat containing 15 3.50E-03 4.24E-03 3.2
LRRC17 Leucine rich repeat containing 17 1.74E-03 2.40E-03 2.8
MARCKS Myristoylated alanine-rich kinase C substrate 3.93E-03 4.50E-03 2.8
NOTCH3 Notch homolog 3 (Drosophila) 1.65E-03 2.36E-03 3.6
PDIR protein disulfide isomerase-related 4.86E-04 1.08E-03 2.1
POSTN Periostin, osteoblast specific factor 1.10E-04 3.15E-04 3.5
RAP1GDS1 RAP1, GTP-GDP dissociation stimulator 1 1.01E-03 1.68E-03 2.1
S100A10 S100 calcium binding protein A10 1.95E-03 2.52E-03 2.8
SIN3A SIN3 homolog A, transcription regulator (yeast) 9.51E-05 3.15E-04 1.7
SLC2A13 Solute carrier family 2 13 5.41E-03 5.85E-03 2.8
TAOK1 TAO kinase 1 1.51E-04 4.03E-04 1.7
TJP1 Tight junction protein 1 (zona occludens 1) 6.87E-04 1.31E-03 1.6
TNC Tenascin C (hexabrachion) 9.20E-05 3.15E-04 5.3
UBE2E3 Ubiquitin-conjugating enzyme E2E 3 8.72E-04 1.52E-03 3.7
WDR1 WD repeat domain 1 4.01E-06 8.01E-05 1.6
WISP1 WNT1 inducible signaling pathway protein 1 3.93E-03 4.50E-03 3.4
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coproteins fibronectin, tenascin C, fibrillin, and laminin
was increased in diseased tendons. Consistent with
active remodeling, increased MMP activity, particularly
of MMP2 and MMP9, has been associated with rup-
tured Achilles tendon [26]. Diseased tendons showed
increased expression of several matrix associated pro-
teins including MMP19, MMP9, MMP13, MMP14,a n d
MMP2.I nc o n t r a s t ,MMP3 expression was decreased in
tendinopathy in both our study and in others [13,22].
We can begin to speculate how MMP activity is regu-
lated in tendinopathy tissue. Diseased tissues showed
increased expression of components of the JAK/STAT
pathway (STAT3, 1.9-fold, and JAK3, 1.8-fold). The
JAK/STAT pathway is known to activate IL4R [27],
which induces expression of IL13RA2 [28]. Expression
of both IL4R and IL13RA2 was elevated in diseased tis-
sue (3.2- and 3.5-fold, respectively). IL13, secreted by T
helper type 2 cells, has anti-inflammatory properties and
through interaction with its receptor IL13RA2 induces
certain MMPs [29] including MMP9 and MMP14 [30].
Together, these findings suggest that activation of the
JAK/STAT pathway may lead to increased MMP
activation.
C h a r de ta l .p r e v i o u s l ys u g g e s t e dt h a tt e n d o np a t h o l -
ogy is linked to formation of excessive fibrocartilage
[31]; however, other prior studies [22] and our current
s t u d yf o u n dl i t t l ee v i d e n c eo fc h o n d r o c y t e - l i k ec e l l s .
Tendinopathy tissue showed decreased expression of a
number of cartilage markers including COMP,b u t
expression of other cartilage markers such as aggrecan
was not altered. In contrast, expression of type I col-
lagen was increased, further supporting the absence of
increased chondrocytic cells in diseased tendons. This is
in contrast to an overuse animal model of tendinopathy
[32,33] that suggested increased formation of fibrocarti-
lage associated with overuse. This discrepancy can possi-
bly be explained by differences in disease severity. The
human samples were collected during surgery following
tendon tear or rupture and represent late stage disease
in which surgical intervention became necessary, while
the animal models represent earlier development of dis-
ease. Furthermore, the human tendon samples represent
Table 4 Genesets regulated in human tendinopathy as
determined by sigpathway
NTk*
Up regulated
HSA04110_CELL_CYCLE 6.52
RNA_PROCESSING 6.44
SPINDLE 6.25
HSA04510_FOCAL_ADHESION 6.10
TGFBETA_LATE_UP 6.02
CELL_CYCLE_KEGG 6.00
CELL_CYCLE 5.94
ST_INTEGRIN_SIGNALING_PATHWAY 5.40
COLLAGEN 5.32
RUIZ_TENASCIN_TARGETS 5.24
I_KAPPAB_KINASE_NF_KAPPAB_CASCADE 5.23
MITOSIS 5.03
INOS_ALL_UP 4.89
Down Regulated
ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY -4.99
G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY -5.01
ELECTRON_TRANSPORT_CHAIN -5.21
MOOTHA_VOXPHOS -6.01
ION_CHANNEL_ACTIVITY -6.20
SUBSTRATE_SPECIFIC_CHANNEL_ACTIVITY -6.27
*As defined in Tian et. al [18].
Table 5 Chemokines regulated in human tendinopathy
Gene Symbol Description p-value q-value Fold Change
BMP1 Bone morphogenetic protein 1 0.000 0.005 1.69
BMP8B Bone morphogenetic protein 8b 0.002 0.011 1.79
CCL2 Chemokine (C-C motif) ligand 2 0.005 0.014 1.74
CMTM4 Chemokine-like factor super family 4 0.008 0.017 1.98
CMTM6 Chemokine-like factor super family 6 0.014 0.023 1.37
IFNGR1 Interferon gamma receptor 1 0.027 0.034 1.42
IL13RA2 Interleukin 13 receptor, alpha 2 0.003 0.011 3.48
IL17D Interleukin 17D 0.008 0.017 0.54
IL6R Interleukin 6 receptor 0.026 0.034 0.73
LEPR Leptin receptor 0.028 0.034 0.49
OSMR Oncostatin M receptor 0.038 0.043 1.81
SP110 SP110 nuclear body protein 0.010 0.019 1.51
STAT2 Signal transducer and activator of transcription 2 0.051 0.054 1.4
STAT3 Signal transducer and activator of transcription 3 0.004 0.013 1.87
TXLNA Taxilin 0.001 0.006 1.39
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Page 7 of 12small biopsies, mostly from the midsubstance. One
might expect any increase in fibrocartilage to occur near
the bone insertion site, an area from which samples
were not collected.
Global pathway analysis identified novel pathways that
are differentially regulated in human tendinopathy
including regulation of genes involved in WNT signal-
ing. Tendinopathy is characterized by increased cellular
infiltration and proliferation. Increases in WNT signal-
ing can promote proliferation and maintain cells in an
undifferentiated state [34] and the regulation of multiple
WNT signaling genes suggests that this pathway is acti-
vated in tendinopathy. Pathway analysis also suggested
an increased regulation of genes involved in integrin sig-
naling. Integrins are receptors involved in cell adhesion
to the extracellular matrix and transmit extracellular sig-
nals into the cell to regulate gene expression. While
many of the genes encoding integrins were only slightly
upregulated, expression of integrin beta 1 (fibronectin
receptor) was significantly increased in tendinopathy
tissue.
We found little direct evidence to support an inflam-
matory response in established human tendinopathy.
Histological evaluation did not identify a significant
number of inflammatory cells and analysis of the gene
expression of inflammatory cytokines identified only a
handful of cytokine genes that were differentially regu-
lated in diseased tendons, although a number of these
are implicated in tendon function and tendon healing.
Expression of the proinflammatory cytokine IL17D was
reduced in diseased tendons. IL17 increases the turn-
over of type I collagen through both inhibiting its
synthesis and promoting its breakdown [35], and mem-
bers of the IL17 cytokine family members are inhibi-
tors of human hematopoietic progenitor proliferation
[36]. The oncostatin M receptor was significantly upre-
gulated in diseased tendons. Oncostatin M contributes
to the release of proteoglycans and the breakdown of
collagens [37]. IL6 is a pro-inflammatory cytokine
important for tendon healing; lack of IL6 prevents
proper tendon healing [38]. Evidence for aberrant reg-
ulation of the IL6 pathway in damaged tendons
Table 6 Change in matrix metallopeptidase gene expression in human tendinopathy
Gene Symbol Description p-value q-value Fold Change
Regulated
MMP2 Matrix metallopeptidase 2 Expressed 7.42E-03 4.82E-02 1.8
MMP3 Matrix metallopeptidase 3 Expressed 5.50E-02 2.38E-01 0.3
MMP14 Matrix metallopeptidase 14 Expressed 1.79E-03 1.66E-02 1.9
MMP19 Matrix metallopeptidase 19 Expressed 1.91E-03 1.66E-02 3.4
Not Regulated
MMP28 Matrix metallopeptidase 28 Expressed 0.09 0.30 1.4
TIMP1 TIMP metallopeptidase inhibitor 1 Expressed 0.10 0.30 1.6
TIMP2 TIMP metallopeptidase inhibitor 2 Expressed 0.37 0.50 1.1
TIMP3 TIMP metallopeptidase inhibitor 3 Expressed 0.26 0.49 0.9
TIMP4 TIMP metallopeptidase inhibitor 4 Expressed 0.71 0.80 0.9
Expressed below limited of detection
MMP1 Matrix metallopeptidase 1 - 0.96 0.96 1.0
MMP7 Matrix metallopeptidase 7 - 0.34 0.49 0.8
MMP8 Matrix metallopeptidase 8 - 0.81 0.84 0.8
MMP9 Matrix metallopeptidase 9 - 0.00 0.02 3.2
MMP10 Matrix metallopeptidase 10 - 0.08 0.30 0.8
MMP12 Matrix metallopeptidase 12 - 0.79 0.84 0.9
MMP13 Matrix metallopeptidase 13 - 0.03 0.14 2.6
MMP15 Matrix metallopeptidase 15 - 0.15 0.35 0.5
MMP16 Matrix metallopeptidase 16 - 0.57 0.67 0.6
MMP17 Matrix metallopeptidase 17 - 0.56 0.67 0.8
MMP20 Matrix metallopeptidase 20 - 0.53 0.67 0.7
MMP21 Matrix metallopeptidase 21 - 0.13 0.33 1.5
MMP23A/B Matrix metallopeptidase 23A/B - 0.34 0.49 0.8
MMP24 Matrix metallopeptidase 2 - 0.29 0.49 0.6
MMP25 Matrix metallopeptidase 25 - 0.18 0.40 0.7
MMP26 Matrix metallopeptidase 26 - 0.34 0.49 0.8
MMP27 Matrix metallopeptidase 27 - 0.33 0.49 0.8
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Page 8 of 12includes decreased expression of the IL6 receptor. IL6
can also signal through STAT3, which was upregulated
in diseased tendons. STAT3 expression has also been
identified in ruptured rotator cuff. However, activation
of STAT3 is mainly induced by proliferating vessels
[39], and since diseased tendons have increased vascu-
lature, many of the observed changes in cytokine
expression may simply be due to this change in vascu-
lature. Therefore, whether these cytokines play a direct
role in tendonopathy requires further study. In addi-
tion to the lack of evidence for direct regulation of
many pro-inflammatory cytokines, there is also indirect
evidence for the absence of inflammatory cytokine
activity. The lack of expression of MMP1 and MMP13,
which are known to be induced by inflammatory cyto-
kines [40], further supports the proposal that pro-
inflammatory cytokines do not play a major role in
tendinopathy at this late stage of disease.
Table 7 Change in collagen gene expression in human tendinopathy
Gene Symbol Description p-value q-value Fold Change
Regulated
COL1A1 Collagen, type I, alpha 1 Expressed 9.37E-03 3.96E-02 1.7
COL1A2 Collagen, type I, alpha 2 Expressed 4.45E-03 3.16E-02 1.6
COL3A1 Collagen, type III, alpha 1 Expressed 1.50E-02 4.28E-02 2.0
COL4A1 Collagen, type IV, alpha 1 Expressed 1.91E-02 4.53E-02 2.7
COL4A2 Collagen, type IV, alpha 2 Expressed 6.09E-03 3.16E-02 2.3
COL5A1 Collagen, type V, alpha 1 Expressed 1.20E-02 4.28E-02 2.0
COL5A2 Collagen, type V, alpha 2 Expressed 3.99E-03 3.16E-02 2.1
COL5A3 Collagen, type V, alpha 3 Expressed 3.02E-03 3.16E-02 2.0
COL6A1 Collagen, type VI, alpha 1 Expressed 2.93E-02 6.18E-02 1.8
COL6A2 Collagen, type VI, alpha 2 Expressed 3.62E-02 6.89E-02 1.8
COL6A3 Collagen, type VI, alpha 3 Expressed 5.45E-03 3.16E-02 1.7
COL8A1 Collagen, type VIII, alpha 1 Expressed 2.49E-02 5.57E-02 2.0
COL8A2 Collagen, type VIII, alpha 2 Expressed 1.48E-02 4.28E-02 1.8
COL10A1 Collagen, type X, alpha 1 Expressed 1.69E-02 4.28E-02 2.1
COL12A1 Collagen, type XII, alpha 1 Expressed 4.10E-03 3.16E-02 2.1
COL18A1 Collagen, type XVIII, alpha 1 Expressed 6.65E-03 3.16E-02 2.2
COL27A1 Collagen, type XXVII, alpha 1 Expressed 1.20E-03 3.16E-02 2.5
Not Regulated
COL7A1 Collagen, type VII, alpha 1 Expressed 0.96 0.96 1.0
COL11A1 Collagen, type XI, alpha 1 Expressed 0.58 0.71 1.2
COL15A1 Collagen, type XV, alpha 1 Expressed 0.51 0.64 1.2
COL16A1 Collagen, type XVI, alpha 1 Expressed 0.12 0.19 1.4
COL21A1 Collagen, type XXI, alpha 1 Expressed 0.34 0.45 1.4
Expressed below limited of detection
COL2A1 Collagen, type II, alpha 1 - 0.21 0.31 0.5
COL4A3 Collagen, type IV, alpha 3 - 0.15 0.23 0.6
COL4A4 Collagen, type IV, alpha 4 - 0.90 0.96 1.0
COL4A5 Collagen, type IV, alpha 5 - 0.71 0.84 0.9
COL4A6 Collagen, type IV, alpha 6 - 0.94 0.96 1.0
COL9A1 Collagen, type IX, alpha 1 - 0.94 0.96 1.0
COL9A2 Collagen, type IX, alpha 2 - 0.05 0.08 1.9
COL11A2 Collagen, type XI, alpha 2 - 0.12 0.19 0.7
COL13A1 Collagen, type XIII, alpha 1 - 0.08 0.13 2.0
COL14A1 Collagen, type XIV, alpha 1 - 0.02 0.04 1.8
COL17A1 Collagen, type XVII, alpha 1 - 0.33 0.45 1.3
COL19A1 Collagen, type XIX, alpha 1 - 0.02 0.04 0.5
COL22A1 Collagen, type XXII, alpha 1 - 0.03 0.07 0.5
COL23A1 Collagen, type XXIII, alpha 1 - 0.75 0.84 1.0
COL24A1 Collagen, type XXIV, alpha 1 - 0.33 0.45 1.3
COL25A1 Collagen, type XXV, alpha 1 - 0.76 0.84 0.9
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In this paper we describe the global transcriptome of
human tendinopathy. Although we have identified a num-
ber of genes that are differentially regulated, the ultimate
roles of these genes and pathways in tendon disease are
yet to be determined. However, we have provided a
resource that we and other investigators can use to explore
the molecular changes associated with tendinopathy.
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Table 8 Kinases regulated in human tendinopathy
Gene Symbol Description pValue q-value Fold Change
ABL2 v-abl Abelson leukemia viral oncogene homolog 2 4.79E-03 7.83E-03 31.0
BMPR2 Bone morphogenetic protein receptor, type II 4.10E-03 7.83E-03 27.0
CAV2 Caveolin 2 1.22E-02 1.44E-02 43.0
CDK6 Cyclin-dependent kinase 6 1.37E-02 1.53E-02 24.0
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DCLK1 Doublecortin-like kinase 1 3.78E-03 7.83E-03 28.0
EML4 Echinoderm microtubule associated protein like 4 9.69E-04 3.15E-03 41.0
EPS8 Epidermal growth factor receptor substrate 8 1.96E-04 1.67E-03 9.0
FGFR1 Fibroblast growth factor receptor 1 5.64E-03 8.46E-03 1.7
ILK Integrin-linked kinase 1.00E-04 1.67E-03 1.6
JAK3 Janus kinase 3 4.62E-03 7.83E-03 1.8
KIAA0220 PI-3-kinase-related kinase SMG-1 2.70E-03 7.02E-03 1.6
KIAA0999 KIAA0999 protein 1.62E-03 4.86E-03 2.1
MAP3K2 Mitogen-activated protein kinase kinase kinase 2 4.82E-03 7.83E-03 1.8
MAP4K5 Mitogen-activated protein kinase kinase kinase 5 1.31E-02 1.50E-02 1.9
MAPK8 Mitogen-activated protein kinase 8 1.42E-02 1.54E-02 2.0
NAGK N-acetylglucosamine kinase 4.16E-03 7.83E-03 1.8
PALM2-AKAP2 A kinase (PRKA) anchor protein 2 2.31E-02 2.37E-02 1.9
PANK2 Pantothenate kinase 2 6.39E-04 2.67E-03 1.6
PAPSS1 3’-phosphoadenosine 5’-phosphosulfate synthase 1 2.35E-04 1.67E-03 1.8
PDLIM5 PDZ and LIM domain 5 8.94E-03 1.09E-02 1.9
PFTK1 PFTAIRE protein kinase 1 4.74E-03 7.83E-03 1.6
PGAM1 Phosphoglycerate mutase 1 (brain) 4.81E-04 2.35E-03 1.6
PI4K2B Phosphatidylinositol 4-kinase type 2 beta 7.80E-03 1.02E-02 1.7
PIK3C2A Phosphoinositide-3-kinase, class 2, alpha 2.28E-02 2.37E-02 1.5
PIP4K2A Phosphatidylinositol-5-phosphate 4-kinase, Iia 7.52E-04 2.67E-03 1.5
PRKAA1 Protein kinase, AMP-activated, alpha 1 5.32E-02 5.32E-02 1.7
PRKD1 Protein kinase D1 7.86E-03 1.02E-02 1.8
PTK9 Twinfilin, actin-binding protein, homolog 1 1.62E-04 1.67E-03 1.7
RIPK2 Receptor-interacting serine-threonine kinase 2 1.84E-03 5.11E-03 1.6
RIPK5 Receptor interacting protein kinase 5 5.91E-03 8.53E-03 1.7
SGMS2 Sphingomyelin synthase 2 3.38E-03 7.76E-03 2.3
SHC1 Src homology 2 domain containing protein 1 2.99E-04 1.67E-03 1.7
SOCS3 Suppressor of cytokine signaling 3 3.07E-03 7.48E-03 1.7
SSA2 TROVE domain family, member 2 2.72E-04 1.67E-03 1.6
TAOK1 TAO kinase 1 1.51E-04 1.67E-03 1.7
TRIM27 Tripartite motif-containing 27 6.94E-04 2.67E-03 1.6
TTN Titin 6.67E-03 9.29E-03 0.2
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